预防克罗恩病并发症的生物治疗

D. Ortiz-Masia
{"title":"预防克罗恩病并发症的生物治疗","authors":"D. Ortiz-Masia","doi":"10.5772/intechopen.90557","DOIUrl":null,"url":null,"abstract":"In recent years, the advent of biological agents has revolutionized the treatment of inflammatory bowel disease (IBD). TNF is a cytokine with a very important role in the pathogenesis of Crohn’s disease (CD), so it is a therapeutic target to highlight. The efficacy and safety of the anti-TNF, IFX and ADA is widely established, becoming two of the therapeutic pillars of CD. Today the experience with other more recent antibodies and stem cells therapy is more limited. Various limitations such as lack of studies, heterogeneity in inclusion criteria, and achievement of objectives make it difficult to establish which treatment is more appropriate in each case and even the superiority between drugs and/or cellular therapy. This chapter will compare the different currently available therapies with special interest in new therapies and their relationship in the prevention of complications of Crohn’s disease.","PeriodicalId":426417,"journal":{"name":"Biological Therapy for Inflammatory Bowel Disease","volume":"46 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biological Therapy in the Prevention of Complications of Crohn\",\"authors\":\"D. Ortiz-Masia\",\"doi\":\"10.5772/intechopen.90557\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent years, the advent of biological agents has revolutionized the treatment of inflammatory bowel disease (IBD). TNF is a cytokine with a very important role in the pathogenesis of Crohn’s disease (CD), so it is a therapeutic target to highlight. The efficacy and safety of the anti-TNF, IFX and ADA is widely established, becoming two of the therapeutic pillars of CD. Today the experience with other more recent antibodies and stem cells therapy is more limited. Various limitations such as lack of studies, heterogeneity in inclusion criteria, and achievement of objectives make it difficult to establish which treatment is more appropriate in each case and even the superiority between drugs and/or cellular therapy. This chapter will compare the different currently available therapies with special interest in new therapies and their relationship in the prevention of complications of Crohn’s disease.\",\"PeriodicalId\":426417,\"journal\":{\"name\":\"Biological Therapy for Inflammatory Bowel Disease\",\"volume\":\"46 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biological Therapy for Inflammatory Bowel Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5772/intechopen.90557\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological Therapy for Inflammatory Bowel Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/intechopen.90557","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

近年来,生物制剂的出现彻底改变了炎症性肠病(IBD)的治疗。TNF是一种在克罗恩病(Crohn’s disease, CD)发病过程中起重要作用的细胞因子,是值得重点关注的治疗靶点。抗肿瘤坏死因子、IFX和ADA的有效性和安全性已得到广泛证实,成为乳糜泻的两大治疗支柱。目前,其他最新抗体和干细胞治疗的经验更为有限。各种限制,如缺乏研究,纳入标准的异质性,以及目标的实现,使得难以确定哪种治疗更适合每种情况,甚至难以确定药物和/或细胞治疗之间的优势。本章将比较目前不同的治疗方法,特别关注新的治疗方法及其在预防克罗恩病并发症中的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Biological Therapy in the Prevention of Complications of Crohn
In recent years, the advent of biological agents has revolutionized the treatment of inflammatory bowel disease (IBD). TNF is a cytokine with a very important role in the pathogenesis of Crohn’s disease (CD), so it is a therapeutic target to highlight. The efficacy and safety of the anti-TNF, IFX and ADA is widely established, becoming two of the therapeutic pillars of CD. Today the experience with other more recent antibodies and stem cells therapy is more limited. Various limitations such as lack of studies, heterogeneity in inclusion criteria, and achievement of objectives make it difficult to establish which treatment is more appropriate in each case and even the superiority between drugs and/or cellular therapy. This chapter will compare the different currently available therapies with special interest in new therapies and their relationship in the prevention of complications of Crohn’s disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信